TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer

被引：0
|
作者：
Liu, H. [1 ]
Schulz, C. O. [1 ]
Regierer, A. C. [1 ]
Dieing, A. [1 ]
Possinger, K. [1 ]
Eucker, J. [1 ]
机构：
[1] Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14625
引用
收藏
页数：1
相关论文
共 50 条
  • [1] TKI258, a novel, multi-targeted tyrosine kinase inhibitor for the treatment of breast cancer
    Liu, Hongyu
    Dieing, Annette
    Lehenbauer-Dehm, Sylvia
    Kuehnhardt, Dagmar
    Regierer, Anne
    Schulz, Carsten
    Storek, Benjamin
    Schwarck, Sandra
    Possinger, Kurt
    Eucker, Jan
    CANCER RESEARCH, 2009, 69
  • [2] TKI258 is an effective multitargeted receptor tyrosine kinase (RTK) inhibitor against prostate cancer models via potent inhibition of FGFR kinase
    Lopes de Menezes, D.
    Hollenbach, P.
    Tang, Y.
    Ye, H.
    Aziz, N.
    Faure, M.
    Niu, H.
    Garcia, P.
    Garrett, E.
    Heise, C.
    EJC SUPPLEMENTS, 2006, 4 (12): : 175 - 175
  • [3] A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors
    Sarker, Debashis
    Molife, Rhoda
    Evans, T. R. Jeffrey
    Hardie, Maryon
    Marriott, Cheryl
    Butzberger-Zimmerli, Priska
    Morrison, Rosemary
    Fox, Judith A.
    Heise, Carla
    Louie, Sharianne
    Aziz, Natasha
    Garzon, Felix
    Michelson, Glenn
    Judson, Ian R.
    Jadayel, Dalal
    Braendle, Edgar
    de Bono, Johann S.
    CLINICAL CANCER RESEARCH, 2008, 14 (07) : 2075 - 2081
  • [4] The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
    Vallo, Stefan
    Mani, Jens
    Stastny, Matthias
    Makarevic, Jasmina
    Juengel, Eva
    Tsaur, Igor
    Bartsch, Georg
    Haferkamp, Axel
    Blaheta, Roman A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 265 - 272
  • [5] The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258
    Stefan Vallo
    Jens Mani
    Matthias Stastny
    Jasmina Makarević
    Eva Juengel
    Igor Tsaur
    Georg Bartsch
    Axel Haferkamp
    Roman A. Blaheta
    Investigational New Drugs, 2013, 31 : 265 - 272
  • [6] TKI258, a Multi-tyrosine Kinase Inhibitor Is Efficacious Against Human Infant/Childhood Lymphoblastic Leukemia In Vitro
    Eucker, Jan
    Zang, Chuanbing
    Zhou, Yongan
    Li, Xinhua
    Habbel, Piet
    Schulz, Carsten-Oliver
    Scholz, Christian
    Liu, Hongyu
    ANTICANCER RESEARCH, 2014, 34 (09) : 4899 - 4907
  • [7] Pazopanib: A novel multitargeted tyrosine kinase inhibitor
    Sonpavde G.
    Hutson T.E.
    Current Oncology Reports, 2007, 9 (2) : 115 - 119
  • [8] CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma
    Trudel, S
    Li, ZH
    Wei, E
    Wiesmann, M
    Chang, H
    Chen, C
    Reece, D
    Heise, C
    Stewart, AK
    BLOOD, 2005, 105 (07) : 2941 - 2948
  • [9] Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
    Andre, Fabrice
    Bachelot, Thomas
    Campone, Mario
    Dalenc, Florence
    Perez-Garcia, Jose M.
    Hurvitz, Sara A.
    Turner, Nicholas
    Rugo, Hope
    Smith, John W.
    Deudon, Stephanie
    Shi, Michael
    Zhang, Yong
    Kay, Andrea
    Porta, Diana Graus
    Yovine, Alejandro
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2013, 19 (13) : 3693 - 3702
  • [10] FGFR genetic alterations or constitutive pathway activation define sensitivity to TKI258, an FGFR kinase inhibitor
    Porta, Diana Graus
    Stamm, Christelle
    Molle, Sandra
    Zumstein-Mecker, Sabine
    Yao, Yao
    Caponigro, Giordano
    Cortes-Cros, Marta
    Garcia-Echeverria, Carlos
    CANCER RESEARCH, 2009, 69
12345